Phase Ib study of melimmune (bivalent) anti-Id antibodies (Ab) in patients with resected melanoma.

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

This Phase IB clinical trial investigates the safety and immunogenicity of the Melimmune vaccine, composed of bivalent anti-idiotype (anti-ID) antibodies, in patients with resected melanoma. The study enrolled patients with no evidence of metastatic disease to evaluate the vaccine's potential to stimulate an immune response and prevent recurrence. Participants received varying doses of Melimmune administered alongside an adjuvant to enhance immune activation. The study's primary endpoint focused on the safety profile of the vaccine, while secondary endpoints assessed the generation of anti-idiotype antibodies and their potential impact on melanoma recurrence rates. Preliminary results suggest that the vaccine is well-tolerated, with a low incidence of adverse effects. Immunogenic responses were observed in a majority of patients, indicating the potential of Melimmune as an adjunct therapy in melanoma management. These findings warrant further investigation in larger, randomized trials.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Journal of Immunotherapy

Link to Full Text

Share

COinS